• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Interstitial Cystitis Therapeutics - Pipeline Assessment and Market Forecasts to 2019 - Product Image

Interstitial Cystitis Therapeutics - Pipeline Assessment and Market Forecasts to 2019

  • Published: January 2012
  • 67 pages
  • GlobalData

Interstitial Cystitis Therapeutics - Pipeline Assessment and Market Forecasts to 2019

Summary

GlobalData, the industry analysis specialist, has released its new report, “Interstitial Cystitis Therapeutics - Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source of information and analysis on the global Interstitial Cystitis Therapeutics market. The report identifies the key trends shaping and driving the global Interstitial Cystitis Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Interstitial Cystitis Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Scope

The report provides information on the key drivers and challenges of the Interstitial Cystitis Therapeutics market. Its scope includes -
- Annualized seven READ MORE >

1
1

1.1 List of Tables
1.2 List of Figures
2 Interstitial Cystitis Therapeutics - Introduction
2.1 Overview
2.2 Epidemiology
2.3 Etiology
2.4 Symptoms
2.5 Diagnosis
2.5.1 Medical History
2.5.2 Physical Examination
2.5.3 Laboratory Tests
2.5.4 Other Investigations
2.6 Pathophysiology
2.7 Treatment and Management Pattern
2.7.1 Oral Pharmacological Approach
2.7.2 Intravesical Therapy
2.7.3 Transcutaneous Electrical Nerve Stimulation
2.7.4 Surgery
2.8 GlobalData Pipeline Report Guidance
3 Interstitial Cystitis Therapeutics - Market Characterization
3.1 Interstitial Cystitis Therapeutics Market Size (2006-2011) - Global
3.2 Interstitial Cystitis Therapeutics Market Forecast (2011-2019) - Global
3.3 Interstitial Cystitis Therapeutics Market Size (2006-2011) - The US
3.4 Interstitial Cystitis Therapeutics Market Forecast (2011-2019) - The US
3.5 Interstitial Cystitis Therapeutics Market Size (2006-2011) - France
3.6 Interstitial Cystitis Therapeutics Market Forecast (2011-2019) - France
3.7 Interstitial Cystitis Therapeutics Market Size (2006-2011) - Germany
3.8 Interstitial Cystitis Therapeutics Market Forecast (2011-2019) - Germany
3.9 Interstitial Cystitis Therapeutics Market Size (2006-2011) - Italy
3.10 Interstitial Cystitis Therapeutics Market Forecast (2011-2019) - Italy
3.11 Interstitial Cystitis Therapeutics Market Size (2006-2011) - Spain
3.12 Interstitial Cystitis Therapeutics Market Forecast (2011-2019) - Spain
3.13 Interstitial Cystitis Therapeutics Market Size (2006-2011) - The UK
3.14 Interstitial Cystitis Therapeutics Market Forecast (2011-2019) - The UK
3.15 Interstitial Cystitis Therapeutics Market Size (2006-2011) - Japan
3.16 Interstitial Cystitis Therapeutics Market Forecast (2011-2019) - Japan
3.17 Drivers and Barriers for the Interstitial Cystitis Therapeutics Market
3.17.1 Drivers for the Interstitial Cystitis Therapeutics Market
3.17.2 Barriers for the Interstitial Cystitis Therapeutics Market
3.18 Opportunity and Unmet Need
3.19 Key Takeaway
4 Interstitial Cystitis Therapeutics - Competitive Assessment
4.1 Overview
4.2 Strategic Competitor Assessment
4.3 Product Profile for Major Marketed Products in the Interstitial Cystitis Therapeutics Market
4.3.1 Elmiron
4.3.2 Rimso-50 (dimethyl sulfoxide)
4.3.3 Tricyclic Antidepressants
4.3.4 Antihistamines
4.4 Key Takeaway
5 Interstitial Cystitis Therapeutics - Pipeline Assessment
5.1 Overview
5.2 Strategic Pipeline Assessment
5.3 Interstitial Cystitis - Pipeline Analysis by Phase of Development
5.3.1 Interstitial Cystitis- Phase III Pipeline
5.3.2 Interstitial Cystitis- Phase II Pipeline
5.3.3 Interstitial Cystitis- Phase I Pipeline
5.3.4 Interstitial Cystitis - Preclinical Pipeline
5.4 Interstitial Cystitis- Pipeline by Mechanism of Action
5.5 Technology Trends Analytical Framework
5.6 Pipeline Molecule Profile
5.6.1 Humira (adalimumab)
5.7 Key Takeaway
6 Interstitial Cystitis Therapeutics - Clinical Trials Mapping
6.1 Clinical Trials by Region and Country
6.2 Clinical Trials by Phase of Clinical Development
6.3 Clinical Trials by Trial Status
6.4 Clinical Trials by Sponsors
6.5 Top Companies Participating in Interstitial Cystitis Clinical Trials
7 Interstitial Cystitis Therapeutics - Strategic Assessment
7.1 Key Events Impacting the Future Market
7.2 Future Market Competition Scenario
8 Interstitial Cystitis Therapeutics - Future Players
8.1 Introduction
8.2 Company Profiles
8.2.1 Abbott Laboratories
8.3 Details of Other Companies in the Pipeline
8.4 Key Takeaway
9 Interstitial Cystitis Therapeutics - Licensing and Partnership Deals
10 Interstitial Cystitis Therapeutics - Appendix
10.1 Definitions
10.2 Acronyms
10.3 Research Methodology
10.3.1 Coverage
10.3.2 Secondary Research
10.3.3 Forecasting
10.3.4 Primary Research
10.3.5 Expert Panel Validation
10.4 Contact Us
10.5 Disclaimer
10.6 Bibliography

1.1 List of Tables
Table 1: Interstitial Cystitis Therapeutics- Treatment Options (Oral Drugs)
Table 2: Interstitial Cystitis Therapeutics- Other Treatment Options
Table 3: Interstitial Cystitis Therapeutics Market, Global, Revenue ($m), 2006-2011
Table 4: Interstitial Cystitis Therapeutics Market, Global, Forecast ($m), 2011-2019
Table 5: Interstitial Cystitis Therapeutics Market, The US, Revenue ($m), 2006-2011
Table 6: Interstitial Cystitis Therapeutics Market, The US, Forecast ($m), 2011-2019
Table 7: Interstitial Cystitis Therapeutics Market, France, Revenue ($m), 2006-2011
Table 8: Interstitial Cystitis Therapeutics Market, France, Forecast ($m), 2011-2019
Table 9: Interstitial Cystitis Therapeutics Market, Germany, Revenue ($m), 2006-2011
Table 10: Interstitial Cystitis Therapeutics Market, Germany, Forecast ($m), 2011-2019
Table 11: Interstitial Cystitis Therapeutics Market, Italy, Revenue ($m), 2006-2011
Table 12: Interstitial Cystitis Therapeutics Market, Italy, Forecast ($m), 2011-2019
Table 13: Interstitial Cystitis Therapeutics Market, Spain, Revenue ($m), 2006-2011
Table 14: Interstitial Cystitis Therapeutics Market, Spain, Forecast ($m), 2011-2019
Table 15: Interstitial Cystitis Therapeutics Market, The UK, Revenue ($m), 2006-2011
Table 16: Interstitial Cystitis Therapeutics Market, The UK, Forecast ($m), 2011-2019
Table 17: Interstitial Cystitis Therapeutics Market, Japan, Revenue ($m), 2006-2011
Table 18: Interstitial Cystitis Therapeutics Market, Japan, Forecast ($m), 2011-2019
Table 19: Interstitial Cystitis Therapeutics - Phase III Clinical Pipeline, 2011
Table 20: Interstitial Cystitis Therapeutics - Phase II Clinical Pipeline, 2011
Table 21: Interstitial Cystitis Therapeutics - Phase I Clinical Pipeline, 2011
Table 22: Interstitial Cystitis Therapeutics - Pre-Clinical Pipeline, 2011
Table 23: Interstitial Cystitis Therapeutics, Global, Clinical Trials, 2011
Table 24: Interstitial Cystitis Therapeutics, Global, Clinical Trials by Phase, 2011
Table 25: Interstitial Cystitis Therapeutics, Global, Clinical Trials by Status of Development, 2011
Table 26: Interstitial Cystitis Therapeutics, Global, Overall Sponsors, 2011
Table 27: Interstitial Cystitis Therapeutics, Global, Prominent Sponsors, 2011
Table 28: Interstitial Cystitis Therapeutics,st Global, Top 10 Companies by Phase, 2011
Table 29: Abbott Laboratories - Interstitial Cystitis Pipeline, 2011
Table 30: Description of Other Companies in the Pipeline, 2011
Table 31: Interstitial Cystitis Therapeutics, Global, Deals, 2011

1.2 List of Figures
Figure 1: Interstitial Cystitis - Impact on Quality of Life
Figure 2: Interstitial Cystitis - Possible Causes
Figure 3: Interstitial Cystitis - Diagnosis Flow and List of Some Confusable Diseases
Figure 4: Interstitial Cystitis - Pathophysiology
Figure 5: Interstitial Cystitis - Oral Pharmacological Approach of Treatment
Figure 6: Interstitial Cystitis - Treatment Algorithm
Figure 7: Interstitial Cystitis Therapeutics Market, Global, Revenue ($m), 2006-2011
Figure 8: Interstitial Cystitis Therapeutics Market, Global, Forecast ($m), 2011-2019
Figure 9: Interstitial Cystitis Therapeutics Market, The US, Revenue ($m), 2006-2011
Figure 10: Interstitial Cystitis Therapeutics Market, The US, Forecast ($m), 2011-2019
Figure 11: Interstitial Cystitis Therapeutics Market, France, Revenue ($m), 2006-2011
Figure 12: Interstitial Cystitis Therapeutics Market, France, Forecast ($m), 2011-2019
Figure 13: Interstitial Cystitis Therapeutics Market, Germany , Revenue ($m), 2006-2011
Figure 14: Interstitial Cystitis Therapeutics Market, Germany, Forecast ($m), 2011-2019
Figure 15: Interstitial Cystitis Therapeutics Market, Italy, Revenue ($m), 2006-2011
Figure 16: Interstitial Cystitis Therapeutics Market, Italy, Forecast ($m), 2011-2019
Figure 17: Interstitial Cystitis Therapeutics Market, Spain, Revenue ($m), 2006-2011
Figure 18: Interstitial Cystitis Therapeutics Market, Spain, Forecast ($m), 2011-2019
Figure 19: Interstitial Cystitis Therapeutics Market, The UK, Revenue ($m), 2006-2011
Figure 20: Interstitial Cystitis Therapeutics Market, The UK, Forecast ($m), 2011-2019
Figure 21: Interstitial Cystitis Therapeutics Market, Japan, Revenue ($m), 2006-2011
Figure 22: Interstitial Cystitis Therapeutics Market, Japan, Forecast ($m), 2011-2019
Figure 23: Opportunity and Unmet Need in the Interstitial Cystitis Therapeutics Market, 2011
Figure 24: Strategic Competitor Assessment of the Marketed Products in Interstitial Cystitis Therapeutics, 2011
Figure 25: Interstitial Cystitis - Clinical Pipeline by Phase of Development (%), 2011
Figure 26: Interstitial Cystitis Therapeutics, Clinical Pipeline by Mechanism of Action (%), 2011
Figure 27: Technology Trends Analytics Framework, 2011
Figure 28: Technology Trends Analytics Framework - Description, 2011
Figure 29: Interstitial Cystitis Therapeutics, Global, Clinical Trials by Country, 2011
Figure 30: Interstitial Cystitis Therapeutics, Global, Clinical Trials by Phase (%), 2011
Figure 31: Interstitial Cystitis Therapeutics, Global, Clinical Trials by Status of Development (%), 2011
Figure 32: Interstitial Cystitis Therapeutics, Global, Overall Sponsors (%), 2011
Figure 33: Interstitial Cystitis Therapeutics, Global, Prominent Sponsors (%), 2011
Figure 34: Interstitial Cystitis Therapeutics, Global, Top Companies by Phase, 2011
Figure 35: Interstitial Cystitis Therapeutics Market, Drivers and Barriers, 2011
Figure 36: Implications for Future Market Competition in the Interstitial Cystitis Therapeutics Market, 2011
Figure 37: Interstitial Cystitis Market, Clinical Pipeline by Company, 2011
Figure 38: GlobalData Market Forecasting Model

GlobalData, the industry analysis specialist, has released its new report, “Interstitial Cystitis Therapeutics - Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source of information and analysis, identifying the key trends shaping and driving the global interstitial cystitis therapeutics market. The report also provides insights on the competitive landscape, emerging players expected to affect the market positioning of current market leaders, and pipeline products within the global interstitial cystitis therapeutics sector. This report has been built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis by GlobalData’s team of industry experts.

Interstitial Cystitis Therapeutics Market is Forecast to Witness Static Growth until 2019

GlobalData analysis shows that the global Interstitial Cystitis (IC) therapeutics market stood at $116.9m in 2006, and grew at a Compound Annual Growth Rate (CAGR) of 5.2% to reach $151m in 2011. GlobalData forecasts that the global IC therapeutics market will grow at a CAGR of 6.3% over the next eight years to reach $245.7m by 2019. The current approved treatment option for IC includes pentosan polysulphate sodium (Elmiron) and dimethyl sulfoxide (Rimso-50), both of which are now off patent. The generic dimethyl sulfoxide was launched in 2002; however, a generic pentosan polysulphate sodium is not yet available. Due to the limited availability of approved therapies, the current line of treatment is dominated by off-label drug options such as antidepressants (amitriptyline), antihistamines (hydroxyzine), analgesics (opioid and non-steroidal) and others. The IC therapeutics market is predicted to experience static growth during the forecast period, primarily due to the limited availability of approved products, low diagnosis rate, and lack of new product approvals during this period.

Interstitial Cystitis Therapeutics Market Is Flooded with Symptomatic Treatment Options

According to GlobalData analysis, the IC therapeutics market is weak at present. The market currently has only two approved treatment options for IC, namely Elmiron (pentosan polysulphate sodium) and Rimso-50 (dimethyl sulfoxide). Elmiron was approved on September 26, 1996, and its patent expired on January 19, 2010. Similarly, Rimso-50 was approved prior to January 1, 1982, and its patent expired before 2002. Elmiron must be orally administered three times a day for at a long treatment regimen of least six months. Rimso-50 is instilled intravesically in the bladder for 15 minutes to reduce inflammation, which is a painful and inconvenient process. Other off-label options include amitriptyline, hydroxyzine, and analgesics. All these available treatment options provide symptomatic relief only, and do not target the underlying cause of disease. These products also have efficacy limitations for IC. Therefore, the IC therapeutics market is currently weak, due to limitations regarding the efficacy and compliance of available products.

Abbott Laboratories

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos